{"id":"https://openalex.org/W2563685161","doi":"https://doi.org/10.1182/blood.v112.11.3.3","title":"Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)","display_name":"Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)","publication_year":2008,"publication_date":"2008-11-16","ids":{"openalex":"https://openalex.org/W2563685161","doi":"https://doi.org/10.1182/blood.v112.11.3.3","mag":"2563685161"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v112.11.3.3","doi":"https://doi.org/10.1182/blood.v112.11.3.3","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.3.3","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038526399","display_name":"Jonathan W. Friedberg","orcid":"https://orcid.org/0000-0002-1420-5563","observed_orcids":["https://orcid.org/0000-0002-1420-5563"]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan W. Friedberg","raw_affiliation_strings":["James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013007045","display_name":"Jeff Porter Sharman","orcid":"https://orcid.org/0000-0001-5611-6115","observed_orcids":["https://orcid.org/0000-0001-5611-6115"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeff Sharman","raw_affiliation_strings":["Stanford University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017430403","display_name":"Julia Schaefer-Cutillo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julia Schaefer-Cutillo","raw_affiliation_strings":["James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076892547","display_name":"Patrick B. Johnston","orcid":"https://orcid.org/0000-0002-3212-3510","observed_orcids":["https://orcid.org/0000-0002-3212-3510"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick B. Johnston","raw_affiliation_strings":["Mayo Clinic Graduate School of Medicine, Rochester, MN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Graduate School of Medicine, Rochester, MN, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081213752","display_name":"Sven de Vos","orcid":"https://orcid.org/0000-0002-6715-4851","observed_orcids":["https://orcid.org/0000-0002-6715-4851"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sven De Vos","raw_affiliation_strings":["David Geffen School of Med. at UCLA, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Med. at UCLA, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085801543","display_name":"Ann Steward LaCasce","orcid":"https://orcid.org/0000-0001-7349-0176","observed_orcids":["https://orcid.org/0000-0001-7349-0176"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann LaCasce","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037882455","display_name":"John Paul Leonard","orcid":"https://orcid.org/0000-0002-5083-1115","observed_orcids":["https://orcid.org/0000-0002-5083-1115"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John P. Leonard","raw_affiliation_strings":["Division of Hem./Onc., Weill Cornell Medical College, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hem./Onc., Weill Cornell Medical College, New York, NY, USA","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016061346","display_name":"Larry Dean Cripe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283055418","display_name":"Indiana University Health","ror":"https://ror.org/01aaptx40","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1283055418","https://openalex.org/I4388446366","https://openalex.org/I592451"]},{"id":"https://openalex.org/I4390039234","display_name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","ror":"https://ror.org/00g1d7b60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039234","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry D. Cripe","raw_affiliation_strings":["Indiana University Simon Cancer Center, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indiana University Simon Cancer Center, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I1283055418","https://openalex.org/I4390039234"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073279579","display_name":"Rajni Sinha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rajni Sinha","raw_affiliation_strings":["Heme/Onc, Emory University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Heme/Onc, Emory University","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109679822","display_name":"S. A. Gregory","orcid":"https://orcid.org/0009-0003-9235-9992","observed_orcids":["https://orcid.org/0009-0003-9235-9992"]},"institutions":[{"id":"https://openalex.org/I1285301757","display_name":"Rush University Medical Center","ror":"https://ror.org/01j7c0b24","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285301757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanie A. Gregory","raw_affiliation_strings":["Section of Hematology & Stem Cell Transplantation, Rush University Medical Center, Chicago, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Hematology & Stem Cell Transplantation, Rush University Medical Center, Chicago, IL, USA","institution_ids":["https://openalex.org/I1285301757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072154632","display_name":"John William Sweetenham","orcid":"https://orcid.org/0000-0002-9873-2060","observed_orcids":["https://orcid.org/0000-0002-9873-2060","https://orcid.org/0009-0000-4315-0015"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Sweetenham","raw_affiliation_strings":["Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080373697","display_name":"Julie Marie Vose","orcid":"https://orcid.org/0000-0003-1015-7434","observed_orcids":["https://orcid.org/0000-0003-1015-7434"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julie M. Vose","raw_affiliation_strings":["Univ. of NE Med. Ctr., Omaha, NE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ. of NE Med. Ctr., Omaha, NE, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030003315","display_name":"Ann M. Lowe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159901","display_name":"Rigel (United States)","ror":"https://ror.org/05j0yvv31","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159901"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann M Lowe","raw_affiliation_strings":["Rigel Pharmaceuticals, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rigel Pharmaceuticals, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210159901"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083342021","display_name":"Ronald Levy","orcid":"https://orcid.org/0000-0003-2061-0650","observed_orcids":["https://orcid.org/0000-0003-2061-0650"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Levy","raw_affiliation_strings":["Oncology, Stanford University, Stanford, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Stanford University, Stanford, CA, USA","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021363179","display_name":"Margaret Ann Shipp","orcid":"https://orcid.org/0000-0002-3949-6897","observed_orcids":["https://orcid.org/0000-0002-3949-6897"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret A. Shipp","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":6.3309,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.96736076,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":96},"biblio":{"volume":"112","issue":"11","first_page":"3","last_page":"3"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.6542999744415283,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.6542999744415283,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.3425000011920929,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/syk-inhibitors","display_name":"SYK inhibitors","score":0.8790000081062317},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.8460000157356262},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9890000224113464},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9459999799728394},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.8600000143051147},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.968999981880188},{"id":"https://openalex.org/keywords/b-cell-receptor-signaling","display_name":"B cell receptor signaling","score":0.7940000295639038},{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-non-hodgkin-lymphoma","display_name":"relapsed/refractory B-cell non-Hodgkin lymphoma","score":0.8489999771118164},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7960000038146973},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8090000152587891},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9509999752044678},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.5370000004768372},{"id":"https://openalex.org/keywords/clinical-trial-results","display_name":"clinical trial results","score":0.3959999978542328}],"concepts":[{"id":"https://openalex.org/C35174551","wikidata":"https://www.wikidata.org/wiki/Q7660502","display_name":"Syk","level":4,"score":0.9504938125610352},{"id":"https://openalex.org/C43907098","wikidata":"https://www.wikidata.org/wiki/Q903924","display_name":"breakpoint cluster region","level":3,"score":0.6316810846328735},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5645146369934082},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5573053956031799},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.546801745891571},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.5189452171325684},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.479361355304718},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46663767099380493},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4028967618942261},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36915451288223267},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3591299057006836},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.35699662566185},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3221176862716675},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.30479976534843445},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1786409616470337},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.15963608026504517}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v112.11.3.3","doi":"https://doi.org/10.1182/blood.v112.11.3.3","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.3.3","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9789000153541565}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.699999988079071}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2321698669","https://openalex.org/W2561663959","https://openalex.org/W1976402300","https://openalex.org/W7100089376","https://openalex.org/W3030306896","https://openalex.org/W2147968449","https://openalex.org/W2552185906","https://openalex.org/W2580237396","https://openalex.org/W7100574066","https://openalex.org/W2020352261"],"abstract_inverted_index":{"Abstract":[0],"Certain":[1],"normal":[2,471],"and":[3,24,27,30,42,61,80,131,161,173,178,187,224,251,264,294,328,382,398,409,421,461,475,491,505,525],"malignant":[4],"B-cells":[5],"rely":[6],"upon":[7,63],"\u201ctonic\u201d":[8],"B-cell":[9,113,253,531],"receptor":[10],"(BCR)-mediated":[11],"survival":[12],"signals.":[13],"BCR":[14,46,56,65],"signaling":[15,483],"induces":[16],"the":[17,20,28,44,93,98,152,164,179,441,448],"phosphorylation":[18],"of":[19,32,50,55,73,97,109,135,155,271,284,307,387,418,425,443],"associated":[21],"Ig":[22],"alpha":[23],"beta":[25],"proteins":[26],"recruitment":[29],"activation":[31],"spleen":[33],"tyrosine":[34],"kinase":[35,487],"(SYK);":[36],"thereafter,":[37],"SYK":[38,74,100,486],"initiates":[39],"downstream":[40],"events":[41],"amplifies":[43],"original":[45],"signal.":[47],"A":[48],"subset":[49],"DLBCL":[51,247,347,417,504],"exhibits":[52],"coordinate":[53],"overexpression":[54],"pathway":[57],"components,":[58],"including":[59,256,288,369],"SYK,":[60],"relies":[62],"tonic":[64],"signaling.":[66],"FosD":[67,156,211,297,516],"is":[68,406],"an":[69,365],"orally":[70],"available":[71],"inhibitor":[72],"under":[75],"development":[76],"for":[77,230,316,393,529],"rheumatoid":[78],"arthritis,":[79],"has":[81],"demonstrated":[82],"significant":[83,501],"in":[84,103,121,210,219,242,273,364,437,440,503,512,526],"vitro":[85],"activity":[86],"against":[87],"BCR-dependent":[88,530],"NHLs.":[89,532],"We":[90,116,234,478],"have":[91,413],"performed":[92],"first":[94,117,153],"clinical":[95],"trial":[96],"oral":[99],"inhibitor,":[101],"FosD,":[102],"patients":[104],"(pts)":[105],"with":[106,198,239,292,371,374,377,380,384,416,423,431,452,514],"a":[107,122,282,434,489,522],"variety":[108],"relapsed":[110],"or":[111],"refractory":[112],"non-Hodgkin\u2019s":[114],"lymphomas.":[115],"enrolled":[118,236],"13":[119],"pts":[120,238,272,280,312,332,390,400,412,430,451,513],"Phase":[123,220,231],"I":[124,221],"component,":[125],"exploring":[126],"two":[127],"dose":[128,314],"levels":[129],"(200":[130],"250":[132,162],"mg":[133,160,226],"BID)":[134],"FosD.":[136],"Pts":[137],"(Follicular":[138],"[FL],":[139],"5;":[140,339],"CLL/SLL,":[141,506],"2;":[142],"mantle":[143],"[MCL],":[144],"3;":[145],"DLBCL,":[146,375],"3)":[147],"were":[148,168,182,304,391,465],"heavily":[149],"pretreated.":[150],"On":[151],"day":[154],"dosing":[157],"at":[158],"200":[159,225,396],"mg,":[163],"maximum":[165],"plasma":[166],"concentrations":[167,194,212],"668":[169],"\u00b1":[170,175,184,189],"258":[171],"ng/mL":[172],"1020":[174],"781":[176],"ng/mL,":[177],"AUC0\u20134":[180],"estimates":[181],"1800":[183],"602":[185],"ng*h/mL":[186],"2590":[188],"1900":[190],"ng*h/mL,":[191],"respectively.":[192],"Plasma":[193],"increased":[195],"approximately":[196],"2-fold":[197],"continued":[199],"administration,":[200],"but":[201],"beyond":[202],"Day":[203],"29":[204],"there":[205,303],"was":[206,222,228,276,298,362,456,510],"no":[207],"apparent":[208],"change":[209],"measured":[213],"over":[214],"time.":[215],"Dose":[216],"limiting":[217],"toxicity":[218],"neutropenia;":[223],"BID":[227],"chosen":[229],"II":[232,275],"evaluation.":[233],"then":[235],"68":[237],"relapsed/refractory":[240],"NHL":[241,254,266],"3":[243],"separate":[244],"disease":[245,345,361,419,509],"cohorts:":[246],"(23);":[248],"FL":[249,354],"(21)":[250],"other":[252],"(24)":[255],"SLL/CLL":[257,351],"(11),":[258],"MCL":[259,357],"(9)":[260],"marginal":[261],"zone/MALT":[262],"(3)":[263],"lymphoplasmacytic":[265],"(1).":[267,330],"The":[268],"median":[269,283],"age":[270],"phase":[274],"61":[277],"(range":[278],"41\u201387);":[279],"received":[281],"5":[285,411],"prior":[286],"therapies,":[287],"ASCT":[289],"(16;":[290],"12":[291,370,467],"DLBCL)":[293],"radioimmunotherapy":[295],"(8).":[296],"overall":[299],"very":[300],"well":[301],"tolerated;":[302],"4":[305,373,376],"cases":[306],"febrile":[308],"neutropenia":[309,317],"reported.":[310],"Eight":[311],"required":[313],"modification":[315],"(2),":[318,320,325],"hypertension":[319],"liver":[321],"function":[322],"test":[323],"abnormalities":[324],"fever":[326],"(1)":[327,460,474],"mucositis":[329],"Six":[331],"withdrew":[333],"before":[334],"initial":[335],"response":[336],"evaluation":[337],"(AE,":[338],"noncompliance,":[340],"1).":[341],"Best":[342],"responses":[343,502],"by":[344,484],"were:":[346],"21%":[348],"(4PR;":[349],"1CR);":[350],"54%":[352],"(6PR);":[353],"10%":[355],"(2PR);":[356],"11%":[358],"(1PR).":[359],"Stable":[360],"observed":[363,511],"additional":[366],"23":[367],"patients,":[368],"FL,":[372],"MCL,":[378],"2":[379],"CLL/SLL":[381,432],"1":[383,422],"MALT.":[385],"As":[386],"7/15/08,":[388],"16":[389],"treated":[392],"more":[394],"than":[395],"days,":[397],"14":[399],"remain":[401],"on":[402],"study.":[403],"Median":[404],"PFS":[405],"4.5":[407],"months,":[408],"only":[410],"died":[414],"(4":[415],"progression":[420],"CLL":[424],"infection":[426],"following":[427],"therapy).":[428],"Several":[429],"experienced":[433],"transient":[435],"increase":[436],"circulating":[438],"lymphocytes":[439],"setting":[442],"responding":[444,450],"nodal":[445],"disease.":[446],"Of":[447],"6":[449],"CLL,":[453],"Zap-70":[454],"status":[455],"positive":[457],"(3),":[458],"negative":[459],"unknown":[462,476],"(2);":[463],"cytogenetics":[464],"trisomy":[466],"(1),":[468,470,472],"del13":[469],"complex":[473],"(2).":[477],"conclude":[479],"that":[480],"disrupting":[481],"BCR-induced":[482],"inhibiting":[485],"represents":[488],"safe":[490],"well-tolerated":[492],"novel":[493],"therapeutic":[494],"approach":[495],"to":[496,500],"NHL.":[497],"In":[498],"addition":[499],"prolonged":[507],"stable":[508],"FL.":[515],"should":[517],"be":[518],"developed":[519],"further,":[520],"as":[521],"single":[523],"agent":[524],"rational":[527],"combinations,":[528]},"counts_by_year":[{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-01-06T00:00:00"}